Login
Companies $PALI
$1.03 +$0.00 (0.0%) After hours
PALISADE BIO, INC. logo

PALISADE BIO, INC.

palisadebio.com

What Do They Do?

Develops oral drug candidates for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, with a lead candidate designed to deliver treatment to the lower intestine.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −410% (Loss)
vs −$2.9M in Q3 FY2025

Lead program The older report centered on an oral digestive-enzyme inhibitor intended for use around surgery to prevent adhesions and improve bowel recovery. The latest report centers on an oral drug candidate for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Who Do They Compete With?

Competes with AbbVie, Johnson & Johnson, Eli Lilly, Takeda, Pfizer, Bristol Myers Squibb, Merck, Genentech, Teva, Morphic Therapeutic, Ventyx, and Spyre Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support